secwatch / observer
8-K filed August 25, 2023, 7:59 PM ET ticker CELU CIK 0001752828
debt confidence high sentiment neutral materiality 0.55

Celularity Inc (CELU): debt financing — Celularity enters $3M loan agreement with CEO Hariri and other lenders

Celularity Inc

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Celularity Inc incurred loan of $3.0 million with Dr. Robert Hariri and two unaffiliated lenders at 15% per year maturing August 21, 2024.

Instrument
loan
Principal
$3.0 million
Counterparty
Dr. Robert Hariri and two unaffiliated lenders
Rate
15% per year
Maturity
August 21, 2024
Event
incurrence
Exact text from the filing
On August 21, 2023, Celularity Inc., or Celularity, entered into a Loan Agreement with its Chairman and Chief Executive Officer, Dr. Robert Hariri, and two unaffiliated lenders, providing for a loan in the aggregate principal amount of $3.0 million (of which Dr. Hariri contributed $1.0 million), or the Loan.
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Celularity Inc entered into Loan Agreement with Dr. Robert Hariri and two unaffiliated lenders valued at $3.0 million (effective 2023-08-21).

Action
entry
Agreement
credit facility
Counterparty
Dr. Robert Hariri and two unaffiliated lenders
Value
$3.0 million
Effective
2023-08-21
Exact text from the filing
On August 21, 2023, Celularity Inc., or Celularity, entered into a Loan Agreement with its Chairman and Chief Executive Officer, Dr. Robert Hariri, and two unaffiliated lenders, providing for a loan in the aggregate principal amount of $3.0 million
View on SEC.gov

114 debt financings filed in the last 30 days. Browse all debt financings →

Celularity Inc filing history →

Source: SEC EDGAR
accession 0001193125-23-221469
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.